A study Comparing the Epigenome of Centenarians and Newborns, Awarded by Diario Médico
News Nov 22, 2012
IDIBELL has received one of the awards for the Best Ideas of the Year, awarded by the publication specializing in medicine and health Diario Médico, by a study concluding that epigenetic marks are degrading over time. The research, which compares the epigenome of centenarians and newborns, was published in June 2012 in the journal Proceedings of the National Academy of Sciences (PNAS). The work has been coordinated by the Director of the Epigenetics and Cancer Biology Program of IDIBELL, Manel Esteller.
While the genome of all cells in the human body, regardless of its appearance and function, is identical, chemical signals that regulate it, known as epigenetic marks, are specific to each human tissue and organ. The surprising result of the work made by Dr. Esteller group is that, even for the same tissue or organ, the epigenome varies depending on the age of the person. The study has shown that the epigenome of a centenarian is altered.
Gala at the National Theatre
The award was presented on November 19 at a gala at the National Theatre of Catalonia. The award was collected by the first author of the paper, the researcher of the Cancer Epigenetics group at IDIBELL Holger A Heyn.
In addition to this award for the IDIBELL research, the Bellvitge University Hospital received an award for the Hospital Efficiency Program, for the centralized management of waiting lists and surgical areas. The initiative has reduced surgical waiting lists and has rescheduled the operating rooms.
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.
Epigenetic Drug Against Mantle Cell LymphomaNews
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a type of cancer characterized by its aggressive behavior, its delayed diagnosis with affectation of different organs and its origin from the lymphocytes B.READ MORE